Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
PharmaEssentia
PharmaEssentia
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Besremi
Ropeginterferon alfa-2b
2021-11-12
Polycythemia vera
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ropeginterferon alfa-2b
hepatitis b
,
chronic hepatitis
,
healthy volunteers/patients
,
chronic hepatitis d
,
myeloid leukemia chronic-phase
,
lymphoma
,
t-cell lymphoma
,
t-cell lymphoma peripheral
,
t-cell lymphoma cutaneous
,
neoplasms
,
hepatitis
,
hepatitis a
,
hepatitis d
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
,
coinfection
,
primary myelofibrosis
,
essential thrombocythemia
,
thrombocytosis
,
chronic hepatitis b
,
hepatitis c
,
chronic hepatitis c
,
infections
,
communicable diseases
,
leukemia
,
bcr-abl positive chronic myelogenous leukemia
,
myeloid leukemia
,
covid-19
,
polycythemia
,
polycythemia vera
,
myeloproliferative disorders
,
herpesviridae infections
,
splenomegaly
Benzocaine
drug interactions
,
liver diseases
,
hepatic insufficiency
,
pancreatic neoplasms
,
adenocarcinoma
,
neuroendocrine tumors
,
cachexia
Gilvetmab
infections
,
chronic hepatitis d
,
hepatitis b
,
chronic hepatitis b
,
communicable diseases
,
hepatitis d
,
hepatitis
,
chronic hepatitis
,
hepatitis a
,
neoplasms
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
Tenofovir
hepatitis c
,
virus diseases
,
breast feeding
,
pregnancy
,
hiv infections
,
acquired immunodeficiency syndrome
,
infections
,
communicable diseases
,
immunologic deficiency syndromes
,
hiv
,
sarcoma
,
kaposi sarcoma
,
hepatitis b
,
hepatitis
,
hepatitis a
,
liver cirrhosis
,
fibrosis
,
biliary liver cirrhosis
,
lipodystrophy
Albinterferon alfa-2b
kidney neoplasms
,
communicable diseases
,
neoplasms
,
renal cell carcinoma
,
hiv
,
brain neoplasms
,
gastrointestinal stromal tumors
,
cholangiocarcinoma
,
primary myelofibrosis
,
liver diseases
,
anemia
,
hypoxia
,
hereditary hemorrhagic telangiectasia
,
telangiectasis
,
pancreatic neoplasms
,
sarcoma
,
kaposi sarcoma
,
melanoma
,
bcr-abl positive chronic myelogenous leukemia
,
leukemia
,
myeloid leukemia
,
acquired immunodeficiency syndrome
,
carcinoma
,
coinfection
,
recurrence
,
menopause
,
neoadjuvant therapy
,
hepatocellular carcinoma
,
liver neoplasms
,
chronic hepatitis d
,
hepatitis d
,
liver transplantation
,
depression
,
depressive disorder
,
neoplasm metastasis
,
disease progression
,
hepatitis
,
hepatitis c
,
hepatitis a
,
chronic hepatitis c
,
chronic hepatitis
,
hiv infections
,
liver cirrhosis
,
hepatitis b
,
chronic hepatitis b
,
infections
,
fibrosis
,
hepacivirus
,
chronic kidney failure
,
kidney diseases
,
homozygote
,
insulin resistance
,
body weight
,
substance-related disorders
,
intravenous substance abuse
,
skin neoplasms
,
cutaneous malignant melanoma
,
non-hodgkin lymphoma
,
lymphoma
,
follicular lymphoma
Nepidermin
actinic keratosis
,
keratosis
,
carcinoma
,
basal cell carcinoma
,
basal cell neoplasms
Globulin, immune
breast neoplasms
Fendrix
meningococcal infections
,
meningitis
,
meningococcal meningitis
,
virus diseases
,
herpesviridae infections
,
hepatitis b virus
,
liver cirrhosis
,
fibrosis
,
hepatitis b
,
hepatitis
,
hepatitis a
,
chronic hepatitis b
,
chronic hepatitis
,
liver diseases
,
gastrointestinal diseases
,
digestive system diseases
,
viral hepatitis human
,
dna virus infections
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use